Immune Therapeutics, Inc.
IMUN
Other OTC0.09
USD
-0.01
- -
CIK
0001559356
ISIN
US45252A3059
CUSIP
45252A305
Return %
Stock
S&P500
1Y
-91.14
26.53
3Y
-99.42
76.60
5Y
-98.89
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Noreen M. Griffin
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2431 Aloma Avenue Winter Park FL United States of America 32792
- IPO Date
- Aug 20, 2010
- CIK
- 0001559356
- Website
- immunetherapeutics.com
- Similar Companies
- Business
- Immune Therapeutics, Inc. (IMUN) operates as a late-stage biopharmaceutical company focused on the acquisition, development, and commercialization of immunotherapies and biopharmaceuticals targeting cancer, chronic inflammation, autoimmune diseases, pain, neurodegenerative disorders, infectious diseases, and viral infections. The company offers partnered programs including JKB-122, a small molecule long-acting TLR4 antagonist licensed for autoimmune hepatitis, non-alcoholic steatohepatitis (NASH), and chronic liver disease; Londonal; and T-cell activation immunotherapies designed for immunomodulation in patients with autoimmune, inflammatory, oncology, and infectious conditions. It pursues internal health-tech platforms such as BiostaxRx for telehealth and inflammaging solutions alongside a smart contract and Healthcare 4.0 electronic records and prescription platform. Founded in 1993 and headquartered in Winter Park, Florida, the company conducts operations primarily in the United States with interests in ex-US and emerging markets. In recent developments, Immune Therapeutics received shareholder approval in March 2023 for a name change to Biostax Corp., which was formalized in October 2023; signed a collaboration agreement in August 2023 with Immgenuity, Inc. to advance novel immunotherapies for HIV remission and other diseases; and continues negotiations for licensing a late-stage hyperphosphatemia treatment while evaluating its technology portfolio for shareholder value.
Critical Analysis: Immune Therapeutics (OTCMKTS:IMUN) & MBX Biosciences (NASDAQ:MBX)
32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
Immune Therapeutics Announces Restructuring Plan
Immune Therapeutics FINRA Approval for 1:1000 Reverse Stock Split